ADIL (Adial Pharmaceuticals) Accounts Receivable : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Adial Pharmaceuticals Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Adial Pharmaceuticals's accounts receivables for the quarter that ended in Dec. 2024 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Adial Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was $0.43.

Adial Pharmaceuticals Accounts Receivable Historical Data

The historical data trend for Adial Pharmaceuticals's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adial Pharmaceuticals Accounts Receivable Chart

Adial Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Receivable

Get a 7-Day Free Trial

Adial Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Accounts Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Adial Pharmaceuticals Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Adial Pharmaceuticals Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Adial Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Adial Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Adial Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(3.751	+	0.75 * 0	+	0.5 * 0	-	0.976
-	0	-	0)	/	6.475
=	0.43

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Adial Pharmaceuticals Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Adial Pharmaceuticals's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Adial Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adial Pharmaceuticals Inc (NAS:ADIL) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

4870 Sadler Road, Suite 300, Glen Allen, VA, USA, 23060

Website

https://www.adialpharma.com

Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.

Executives

Kevin Schuyler	director	1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Stilley William B. Iii	director, 10 percent owner, officer: Chief Executive Officer	1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Newman James W. Jr.	director	1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Cary J Claiborne	director	3056 SENECA CHIEF TRAIL, ELLICOTT CITY MD 21042
Bankole A. Johnson	director, 10 percent owner	1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Jack W Reich	director	C/O COLLATERAL THERAPEUTICS, 11622 EL CAMINO REAL, SAN DIEGO CA 92130
Tony Goodman	director	1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
J. Kermit Anderson	director	1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Joseph Truluck	officer: COO and CFO	1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Robertson H. Gilliland	director	1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
En Fidecomiso De Mi Vida 11/23/2010 Trust	10 percent owner	11024 GAITHER FARM ROAD, ELLICOTT CITY MD 21042